We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+39.96%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$3.39B
AUM Growth
+$491M
Cap. Flow
-$110M
Cap. Flow %
-3.26%
Top 10 Hldgs %
67.91%
Holding
89
New
9
Increased
10
Reduced
15
Closed
13
Avg Time Held Equity + Options
4.5 quarters
Top 10 Avg Time Held Equity + Options
6 quarters
Top 20 Avg Time Held Equity + Options
5.2 quarters
Avg Time Held Equity only
4.6 quarters
Top 10 Avg Time Held Equity only
6 quarters
Top 20 Avg Time Held Equity only
5.2 quarters

Top Buys

Rank Stock Value
1
SWTX icon
SpringWorks Therapeutics
SWTX
+$99.2M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$75.1M
3
GOSS icon
Gossamer Bio
GOSS
+$51.6M
4
KYMR icon
Kymera Therapeutics
KYMR
+$21M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$13.5M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$118M
2
RVMD icon
Revolution Medicines
RVMD
+$54.4M
3
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$53.7M
4
CERE icon
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$43.5M
5
ARGX icon
argenx
ARGX
+$39.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.27%
2 Financials 0.56%
3 Miscellaneous 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PRTA icon
1
Prothena Corp
PRTA
$429M
$702M 20.73%
11,584,280
– –
2018 Q4
15 quarters
APLS icon
2
DELISTED
Apellis Pharmaceuticals
APLS
$354M 10.45%
5,183,431
– –
2021 Q4
3 quarters
SRPT icon
3
Sarepta Therapeutics
SRPT
$1.74B
$332M 9.79%
2,999,453
+131,308
+5% +$13.2M
2022 Q1
2 quarters
ANAB icon
4
AnaptysBio
ANAB
$1.36B
$192M 5.66%
7,521,024
– –
2019 Q4
11 quarters
ARVN icon
5
Arvinas
ARVN
$447M
$139M 4.1%
3,123,300
– –
2021 Q4
3 quarters
XNCR icon
6
Xencor
XNCR
$1.75B
$137M 4.05%
5,282,516
+100
+0% +$2.86K
2018 Q4
15 quarters
LKFT icon
7
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
$136M 4.02%
3,197,500
– –
2021 Q3
4 quarters
MORF icon
8
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$112M 3.3%
3,951,566
– –
2019 Q2
13 quarters
SWTX icon
9
DELISTED
SpringWorks Therapeutics
SWTX
$98.7M 2.91%
+3,460,208
New +$99.2M
2022 Q3
0 quarters
ACAD icon
10
Acadia Pharmaceuticals
ACAD
$3.21B
$98M 2.89%
5,991,479
– –
2021 Q4
3 quarters
RLAY icon
11
Relay Therapeutics
RLAY
$3.8B
$93.1M 2.75%
4,163,824
+440,283
+12% +$9.66M
2020 Q3
8 quarters
KURA icon
12
Kura Oncology
KURA
$874M
$90.7M 2.68%
6,638,371
– –
2015 Q4
27 quarters
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$70.9M 2.09%
+1,015,572
New +$75.1M
2022 Q3
0 quarters
ZLAB icon
14
Zai Lab
ZLAB
$2.59B
$69.4M 2.05%
2,030,252
-401,633
-17% -$17.2M
2022 Q1
2 quarters
GOSS icon
15
Gossamer Bio
GOSS
$59.7M
$49.8M 1.47%
+52,011
New +$51.6M
2022 Q3
0 quarters
ALLO icon
16
Allogene Therapeutics
ALLO
$446M
$48.5M 1.43%
4,488,200
– –
2022 Q2
1 quarter
RNAM
17
DELISTED
Avidity Biosciences
RNAM
$47.3M 1.4%
2,899,285
+139,780
+5% +$2.67M
2020 Q2
9 quarters
DSGN icon
18
Design Therapeutics
DSGN
$612M
$42.1M 1.24%
2,519,268
-114,910
-4% -$2.29M
2021 Q1
6 quarters
SGEN
19
DELISTED
Seagen Inc. Common Stock
SGEN
$39.1M 1.15%
285,793
-722,835
-72% -$118M
2022 Q2
1 quarter
ALEC icon
20
Alector
ALEC
$209M
$38.4M 1.13%
4,056,548
– –
2021 Q1
6 quarters
RVMD icon
21
Revolution Medicines
RVMD
$40.4B
$35.5M 1.05%
1,801,847
-2,476,222
-58% -$54.4M
2022 Q1
2 quarters
AVIR icon
22
Atea Pharmaceuticals
AVIR
$399M
$35.2M 1.04%
6,184,861
-155,778
-2% -$1.19M
2021 Q4
3 quarters
EWTX icon
23
Edgewise Therapeutics
EWTX
$3.94B
$34.4M 1.01%
3,493,194
+1,133,386
+48% +$11.5M
2021 Q1
6 quarters
TSVT icon
24
DELISTED
2seventy bio
TSVT
$34.1M 1.01%
2,341,313
-1,154,630
-33% -$17.1M
2021 Q4
3 quarters
NUVB icon
25
Nuvation Bio
NUVB
$1.66B
$31.1M 0.92%
13,896,543
– –
2021 Q1
6 quarters
1
2 3 4

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q3 2022 Portfolio in Review

As of Q3 2022, EcoR1 Capital held 89 positions worth $3.39B, up 17% from $2.9B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

EcoR1 Capital withdrew a net $110M in Q3 2022, closing 13 positions and reducing 15 holdings. Its most notable exit was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $43.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials and Miscellaneous.

Against the trend, EcoR1 Capital opened a new position in SpringWorks Therapeutics worth $98.7M.

  • EcoR1 Capital's largest Q3 2022 buy was SpringWorks Therapeutics: 3,460,208 shares worth $98.7M.
  • EcoR1 Capital added most to Centessa Pharmaceuticals in Q3 2022, an estimated $13.5M increase.
  • EcoR1 Capital's biggest Q3 2022 reduction was Seagen Inc. Common Stock, cutting an estimated $118M.
  • EcoR1 Capital fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2022, selling an estimated $43.5M.
  • EcoR1 Capital's ten largest holdings make up 68% of its $3.39B portfolio in Q3 2022.
  • EcoR1 Capital opened 9 new positions and closed 13 in Q3 2022.
  • EcoR1 Capital's portfolio value rose 17% quarter-over-quarter to $3.39B.

Based on EcoR1 Capital's 13F filing for Q3 2022, filed 14 Nov 2022.